Crispr Therapeutics Stock News

Concorde Asset Management LLC grew its stake in CRISPR Therapeutics AG (NASDAQ:CRSP) by 215.6% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 4,782 shares of the companys stock after acquiring an additional 3,267 shares during the period. Concorde Asset Management LLCs holdings in CRISPR Therapeutics were []

In the last trading session, 2.55 million CRISPR Therapeutics AG (NASDAQ:CRSP) shares changed hands as the companys beta touched 2.09. With the companys per share price at $78.39 changed hands at $7.27 or 10.22% during last session, the market valuation stood at $6.58B. CRSPs last price was a discount, traded about -180.9% off its 52-week CRISPR Therapeutics AG (NASDAQ: CRSP) Is Expected To Soar To Higher Prices In The Months To Come. Read More »

Cowen initiated coverage on shares of CRISPR Therapeutics (NASDAQ:CRSP) in a research note issued on Monday, PriceTargets.com reports. The firm set a market perform rating on the stock. Other equities research analysts have also issued research reports about the company. Barclays lowered their target price on CRISPR Therapeutics from $160.00 to $148.00 and set an []

The gene-editing specialist''s share price is now down roughly 54% in 2021.

The gene-editing specialist's share price is now down roughly 54% in 2021.

The rise in the availability of government and private funding and the adoption of CRISPR technology are the key factors driving the Continue reading on Medium »

CRISPR Therapeutics AG's (CRSP) CEO Sam Kulkarni at Piper Sandler 33rd Annual Virtual Healthcare Conference (Transcript)

One of the company's co-founders won a Nobel prize in chemistry for her work done on the CRISPR technology.

CRISPR Therapeutics' (CRSP) CEO Samarth Kulkarni on 4th Annual Evercore ISI HealthCONx Conference

All the elements are in place for a rebound.

Foundations Investment Advisors LLC boosted its stake in CRISPR Therapeutics AG (NASDAQ:CRSP) by 79.4% in the third quarter, Holdings Channel reports. The firm owned 4,041 shares of the company’s stock after purchasing an additional 1,788 shares during the quarter. Foundations Investment Advisors LLC’s holdings in CRISPR Therapeutics were worth $414,000 at the end of the […]

ZUG, Switzerland and CAMBRIDGE, Mass., Nov. 23, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for ser